InfuSystem Holdings, Inc. (NYSE:INFU) Stock Position Lowered by Meros Investment Management LP

Meros Investment Management LP lessened its position in InfuSystem Holdings, Inc. (NYSE:INFU) by 0.2% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 614,927 shares of the company’s stock after selling 1,211 shares during the quarter. InfuSystem makes up about 1.9% of Meros Investment Management LP’s holdings, making the stock its 26th biggest holding. Meros Investment Management LP owned 2.89% of InfuSystem worth $4,120,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. BNP Paribas Financial Markets lifted its position in InfuSystem by 66.4% in the 3rd quarter. BNP Paribas Financial Markets now owns 4,076 shares of the company’s stock worth $27,000 after buying an additional 1,626 shares in the last quarter. Williams & Novak LLC purchased a new stake in InfuSystem in the 3rd quarter worth approximately $70,000. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in InfuSystem in the 3rd quarter worth approximately $87,000. Rhumbline Advisers raised its holdings in shares of InfuSystem by 13.8% during the 2nd quarter. Rhumbline Advisers now owns 17,658 shares of the company’s stock valued at $121,000 after purchasing an additional 2,145 shares in the last quarter. Finally, Marshall Wace LLP bought a new position in shares of InfuSystem during the 2nd quarter valued at $131,000. Hedge funds and other institutional investors own 71.13% of the company’s stock.

InfuSystem Trading Down 2.8 %

NYSE:INFU opened at $8.99 on Wednesday. InfuSystem Holdings, Inc. has a 1 year low of $5.74 and a 1 year high of $10.99. The firm has a fifty day moving average price of $7.76. The company has a quick ratio of 1.59, a current ratio of 1.98 and a debt-to-equity ratio of 0.50. The firm has a market cap of $191.16 million, a price-to-earnings ratio of 149.83 and a beta of 1.53.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on INFU shares. B. Riley started coverage on shares of InfuSystem in a report on Thursday, September 26th. They set a “buy” rating and a $13.00 price target on the stock. StockNews.com upgraded shares of InfuSystem from a “buy” rating to a “strong-buy” rating in a report on Friday, November 8th.

Insider Activity at InfuSystem

In other InfuSystem news, CEO Richard Dilorio sold 20,000 shares of the firm’s stock in a transaction on Monday, November 25th. The shares were sold at an average price of $9.32, for a total value of $186,400.00. Following the sale, the chief executive officer now directly owns 436,659 shares in the company, valued at $4,069,661.88. This trade represents a 4.38 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 10.20% of the stock is currently owned by company insiders.

About InfuSystem

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.